Clinical Trials Logo

Non-segmental Vitiligo clinical trials

View clinical trials related to Non-segmental Vitiligo.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04942860 Completed - Clinical trials for Non-segmental Vitiligo

The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo

EVRAM
Start date: October 1, 2019
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate the influence of two concentrations of methotrexate on vitiligous lesions in patients with non-segmental vitiligo

NCT ID: NCT04927975 Completed - Clinical trials for Non-Segmental Vitiligo

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Start date: June 16, 2021
Phase: Phase 2
Study type: Interventional

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in disease activity will be assessed. Upadacitinib is being evaluated for the treatment of non-segmental vitiligo. The study will enroll approximately 160 participants aged 18-65 with non-segmental vitiligo in 5 treatment arms across 35 sites worldwide. Participants will either receive study drug vs placebo oral tablets once daily (QD) for 24 weeks (Period A). In Period B (up to 52 weeks), participants who received placebo during the first 24 weeks will switch to study drug. Participants who received study drug during the first 24 weeks, will continue to receive study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

NCT ID: NCT04487860 Completed - Clinical trials for Non-segmental Vitiligo

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Start date: January 6, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.

NCT ID: NCT04057573 Completed - Clinical trials for Non-segmental Vitiligo

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Start date: October 3, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

NCT ID: NCT04052425 Completed - Clinical trials for Non-segmental Vitiligo

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Start date: September 20, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

NCT ID: NCT03247400 Completed - Clinical trials for Non-segmental Vitiligo

The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo

EVRAAS
Start date: December 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to evaluate the influence of simvastatin and atorvastatin on vitiligous lesions in patients with non-segmental vitiligo.